Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
September 16, 2019 07:00 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
Data show >90% knockdown of TTR following administration in healthy volunteers Positive safety and tolerability profile for LICA platform-based therapy Phase 3 program on track to start later...
Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings
August 29, 2019 07:00 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
Multiple presentations on the long-term efficacy and safety of TEGSEDI® (inotersen) in patients with polyneuropathy caused by hATTR Amyloidosis Topline data results to be presented from the Phase 1...
New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome
August 07, 2019 17:10 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals
Mean triglyceride levels decreased 77% in volanesorsen-treated patients versus an 18% increase in patients in placebo group Akcea launching WAYLIVRA in the European Union BOSTON and CARLSBAD, Calif,...
Akcea Reports Financial Results and Highlights for Second Quarter 2019
August 06, 2019 16:05 ET
|
Akcea Therapeutics, Inc.
Achieved Second Quarter 2019 TEGSEDI® (inotersen) Global Net Product Revenues of $10 Million Conference Call Webcast Tuesday, August 6, 4:30 p.m. ET at www.akceatx.com BOSTON, Aug. 06, 2019 (GLOBE...
Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy
August 06, 2019 16:05 ET
|
Akcea Therapeutics, Inc.
BOSTON, Mass. and CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:...
Akcea Therapeutics to Hold Second Quarter 2019 Financial Results Webcast
July 29, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, July 29, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 6th...
hATTR Compass™ Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch
July 16, 2019 07:00 ET
|
Akcea Therapeutics, Inc.; Ambry Genetics Corporation
BOSTON and Aliso Viejo, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ambry Genetics Corporation (“Ambry”), a...
Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Academy of Neurology Annual Congress
June 26, 2019 07:00 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON and CARLSBAD, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting
June 20, 2019 16:38 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON and CARLSBAD, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
Akcea Therapeutics to Present at Upcoming Investor Conferences
May 28, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, May 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with...